Published in AIDS Weekly, May 10th, 2004
The placement agent is not required to sell a minimum number or dollar amount of shares.
GenVec plans to use the net proceeds of this financing for product development activities, including support of clinical trials, expansion of manufacturing capabilities, and other general corporate purposes.
GenVec is a publicly held biopharmaceutical company developing therapies that improve patient care in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.